Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1576 AL 1590

Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia

Yassine HN, Arellanes IC, Mazmanian A, De La Cruz L, Martinez J, Contreras L, Kono N, Liu BS, Badie D, Bantugan MA, Grindon A, Urich T, D'Orazio L, Emmanuel BA, Chui HC, Mack WJ, Harrington MG, Braskie MN, Schneider LS.

J Prev Alzheimers Dis. 2023;10(4):810-820. doi: 10.14283/jpad.2023.77.

Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease

Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group.

N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430.

The Major Hypotheses of Alzheimer's Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment

Cáceres C, Heusser B, Garnham A, Moczko E.

Cells. 2023 Nov 21;12(23):2669. doi: 10.3390/cells12232669.

Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease

Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, Maldonado J, Donahue MJ, Schultz D, Coyne TM, Charidimou A, Schrag M.

Nat Commun. 2023 Dec 12;14(1):8220. doi: 10.1038/s41467-023-43933-5.

People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare

Wahlberg K, Winblad B, Cole A, Herring WL, Ramsberg J, Torontali I, Visser PJ, Wimo A, Wollaert L, Jönsson L.

J Intern Med. 2024 Mar;295(3):281-291. doi: 10.1111/joim.13759. Epub 2023 Dec 14.

2D nanostructures: Potential in diagnosis and treatment of Alzheimer's disease

Tufail S, Sherwani MA, Shamim Z, Abdullah, Goh KW, Alomary MN, Ansari MA, Almosa AA, Ming LC, Abdullah ADI, Khan FB, Menhali AA, Mirza S, Ayoub MA.

Biomed Pharmacother. 2024 Jan;170:116070. doi: 10.1016/j.biopha.2023.116070. Epub 2023 Dec 31.

Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities

Hardy J, Schott JM.

Neurology. 2024 Feb 13;102(3):e208096. doi: 10.1212/WNL.0000000000208096. Epub 2023 Dec 28.

Bipolar Disorder and Manic-Like Symptoms in Alzheimer's, Vascular and Frontotemporal Dementia: A Systematic Review

Elefante C, Brancati GE, Torrigiani S, Amadori S, Ricciardulli S, Pistolesi G, Lattanzi L, Perugi G.

Curr Neuropharmacol. 2023;21(12):2516-2542. doi: 10.2174/1570159X20666220706110157.

Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment

Damiano RF, Loureiro JC, Pais MV, Pereira RF, Corradi MM, Di Santi T, Bezerra GAM, Radanovic M, Talib LL, Forlenza OV.

Braz J Psychiatry. 2023 Mar 11;45(1):46-49. doi: 10.47626/1516-4446-2022-2767.

Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease

Garcia MJ, Leadley R, Lang S, Ross J, Vinand E, Ballard C, Gsteiger S.

J Alzheimers Dis. 2023;91(1):151-167. doi: 10.3233/JAD-220471.

Role of Flavonoids in Management of Various Biological Targets in Alzheimer's Disease: Evidence from Preclinical to Clinical Studies

Alharbi KS, Javed Shaikh MA, Imam SS, Alshehri S, Ghoneim MM, Almalki WH, Singh SK, Kumar D, Kumar AP, Dua K, Chellappan DK, Paudel KR, Gupta G.

Curr Med Chem. 2023;30(18):2061-2074. doi: 10.2174/0929867330666221122115212.

Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline

Caprioglio C, Ribaldi F, Visser LNC, Minguillon C, Collij LE, Grau-Rivera O, Zeyen P, Molinuevo JL, Gispert JD, Garibotto V, Moro C, Walker Z, Edison P, Demonet JF, Barkhof F, Scheltens P, Alves IL, Gismondi R, Farrar G, Stephens AW, Jessen F, Frisoni GB, Altomare D; AMYPAD consortium.

JAMA Netw Open. 2023 Jan 3;6(1):e2250921. doi: 10.1001/jamanetworkopen.2022.50921.

Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease

Lansdall CJ, McDougall F, Butler LM, Delmar P, Pross N, Qin S, McLeod L, Zhou X, Kerchner GA, Doody RS.

J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102.

Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials

Henley B, Okafor M, Kulshreshtha A, Trammell A, Hajjar I.

Int J Stroke. 2023 Jul;18(6):736-744. doi: 10.1177/17474930231153313. Epub 2023 Jan 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias